Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Bozorlar
Skriner
Yangiliklar
Biz haqimizda

RXST - RxSight, Inc. So'nggi Yangiliklar | Finranks

Home

RXST

R

RxSight, Inc. (RXST)

NGM – Real vaqt narxi. Valyuta: USD

6.26

-0.23 (-3.54%)

Yopilishda: Mar 27, 2026, 4:00 PM EDT

6.26

0.00 (0.00%)

Bozordan keyin: Mar 27, 2026, 4:34 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

RxSight, Inc. (RXST) Q4 2025 Earnings Call Transcript

RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) Reports Q4 Loss, Beats Revenue Estimates

RxSight, Inc. (RXST) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.23. This compares to earnings of $0.03 per share a year ago.

Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline

Earnings Preview: RxSight, Inc. (RXST) Q4 Earnings Expected to Decline

RxSight (RXST) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

RxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026

ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. (“RxSight” or the “Company”) (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of RxSight, Inc. - RXST

NEW YORK, Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of RxSight, Inc. ("RxSight" or the "Company") (NASDAQ: RXST). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

Videolar

No Data

There is no data to display